The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksHigh Impact•13 February 2026•

1 min read

West Pharmaceutical Services Beats Q4 EPS, Raises FY26 Guidance on Strong Demand

3D metallic 'PVH' text with 'CALVIN KLEIN' and 'TOMMY HILFIGER' names. Upward trend line, 'EARNINGS BEAT', 'REVENUE: +14%', and '2026 GUIDANCE' on an orange background.

West Pharmaceutical Services (NYSE:WST) reported robust fourth-quarter results, with adjusted EPS reaching $2.04, significantly surpassing analyst expectations by $0.21. The company's revenues for the quarter also stood strong at $805 million, reflecting solid financial performance. Building on this momentum, West Pharmaceutical Services raised its financial guidance for fiscal year 2026, now projecting adjusted EPS between $7.85 and $8.20. The updated outlook also anticipates organic revenue growth of 5-7%, signaling management's confidence in future prospects. This strong performance was attributed to high-value product components and robust market demand. Despite some near-term operational constraints, the company's raised guidance indicates a positive trajectory for future performance.